


Supplementary Figure 1: Expression of SRPX2 and RAB31 in different types of cancer cell lines. Representative SRPX2 and RAB31 mRNA expression in tumor cells from CCLE analysis (shown in red frame). Expression of SRPX2 mRNA ranked fourth highest in a variety of cancer cell lines, and expression of RAB31 mRNA ranked thirteenth highest in a variety of cancer cell lines.



Supplementary table 1. Demographics and Clinicopathological Characteristics of the Sets of Patients with Resectable PDAC

Features	Training set (n=79)	Validation set (n=121)	<i>P</i> value
Age (years, median [range])	61 (39-81)	62 (38-78)	0.802
Sex (female/male) (%)	35/44 (44.3/55.7)	49/72 (40.5/59.5)	0.661
Tumor location (head/body, tail) (%)	41/38 (51.9/48.1)	65/56 (53.7/46.3)	0.801
Neural invasion (yes/no) (%)	64/15 (81.0/19.0)	90/31 (74.4/25.6)	0.276
Tumor size (cm, mean \pm SD)	5.12 \pm 1.833	4.88 \pm 1.824	0.517
Preoperative CA19-9 (U/mL, median) (range)	202 (1-1993)	201 (0-8733)	0.543
8 th edition TNM stage (I/II/III) (%)	21/41/17 (26.6/51.9/21.5)	43/50/28 (35.5/41.3/23.1)	0.297
SRPX2 expression (High/Low) (%)	42/37 (53.2/46.8)	73/48 (60.3/39.7)	0.316
RAB31 expression (High/Low) (%)	35/44 (44.3/55.7)	68/53 (56.2/43.8)	0.100

Note: TNM: tumor node metastasis; CA19-9: carbohydrate antigen 19-9.